Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Crinetics Pharmaceuticals, Inc. or Liquidia Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Crinetics Pharmaceuticals, Inc. and Liquidia Corporation compare based on key financial metrics to determine which better meets your investment needs.

About Crinetics Pharmaceuticals, Inc. and Liquidia Corporation

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Latest Pharmaceuticals and Crinetics Pharmaceuticals, Inc., Liquidia Corporation Stock News

As of May 7, 2026, Crinetics Pharmaceuticals, Inc. had a $4.6 billion market capitalization, compared to the Pharmaceuticals median of $635.8 million. Crinetics Pharmaceuticals, Inc.’s stock is down 18.3% in 2026, down 2.5% in the previous five trading days and up 42.45% in the past year.

Currently, Crinetics Pharmaceuticals, Inc. does not have a price-earnings ratio. Crinetics Pharmaceuticals, Inc.’s trailing 12-month revenue is $7.7 million with a % net profit margin. As of May 7, 2026, Crinetics Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.828 per share for the current fiscal year. Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.

As of May 7, 2026, Liquidia Corporation had a $3.8 billion market cap, putting it in the 63rd percentile of all stocks. Liquidia Corporation’s stock is up 21.6% in 2026, up 9.9% in the previous five trading days and up 172.16% in the past year.

Currently, Liquidia Corporation does not have a price-earnings ratio. Liquidia Corporation’s trailing 12-month revenue is $158.3 million with a -43.5% net profit margin. As of May 7, 2026, Liquidia Corporation has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $2.578 per share for the current fiscal year. Liquidia Corporation does not currently pay a dividend.

How We Compare Crinetics Pharmaceuticals, Inc. and Liquidia Corporation Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Crinetics Pharmaceuticals, Inc. and Liquidia Corporation’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Crinetics Pharmaceuticals, Inc. and Liquidia Corporation Stock Value Grades

Company	Ticker	Value
Crinetics Pharmaceuticals, Inc.	CRNX	F
Liquidia Corporation	LQDA	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Crinetics Pharmaceuticals, Inc. has a Value Score of 8, which is Ultra Expensive. Liquidia Corporation has a Value Score of 4, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc. or Liquidia Corporation has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc. or Liquidia Corporation is the better investment when it comes to value.

Crinetics Pharmaceuticals, Inc. and Liquidia Corporation Growth Grades

Company	Ticker	Growth
Crinetics Pharmaceuticals, Inc.	CRNX	F
Liquidia Corporation	LQDA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Crinetics Pharmaceuticals, Inc. has a Growth Score of 12, which is Very Weak. Liquidia Corporation has a Growth Score of 18, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc. or Liquidia Corporation has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc. or Liquidia Corporation is the better investment when it comes to sustainable growth.

Crinetics Pharmaceuticals, Inc. and Liquidia Corporation’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Crinetics Pharmaceuticals, Inc.	CRNX	C
Liquidia Corporation	LQDA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Crinetics Pharmaceuticals, Inc. has a Earnings Estimate Score of 41, which is Neutral. Liquidia Corporation has a Earnings Estimate Score of 39, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc. or Liquidia Corporation has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc. or Liquidia Corporation is the better investment when it comes to estimate revisions.

Other Crinetics Pharmaceuticals, Inc. and Liquidia Corporation Grades

In addition to Estimate Revisions, Value and Growth, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Crinetics Pharmaceuticals, Inc. and Liquidia Corporation pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Crinetics Pharmaceuticals, Inc. or Liquidia Corporation Stock?

Overall, Crinetics Pharmaceuticals, Inc. stock has a Value Score of 8, Growth Score of 12 and Estimate Revisions Score of 41.

Liquidia Corporation stock has a Value Score of 4, Growth Score of 18 and Estimate Revisions Score of 39.

Comparing Crinetics Pharmaceuticals, Inc. and Liquidia Corporation’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.